세계의 차세대 종양학 디바이스 및 솔루션 시장 : 컴포넌트, 암 유형, 최종 사용자별 예측(2025-2030년)

The Next-Generation Oncology Devices & Solutions Market was valued at USD 15.62 billion in 2023, expected to reach USD 18.97 billion in 2024, and is projected to grow at a CAGR of 21.15%, to USD 59.84 billion by 2030.

The scope and definition of next-generation oncology devices and solutions encompass advanced technologies and methods developed to diagnose, monitor, and treat cancer more effectively. With precision medicine and personalized treatment approaches at the core, these innovations leverage molecular diagnostics, AI-driven analytics, and minimally invasive surgical tools. The necessity arises from the increasing cancer prevalence and the urgent need for enhanced accuracy in early detection and tailored treatment plans. Applications span across various types of cancers, and end-use environments include diagnostic labs, hospitals, and specialized cancer treatment centers. Market insights reveal that key growth factors include technological advancements in imaging and AI, rising healthcare expenditures, and increasing awareness regarding early cancer diagnosis. Potential opportunities lie in expanding telemedicine solutions for cancer care, which could drastically improve patient accessibility to cutting-edge treatments. Furthermore, enhancing collaboration with tech firms can drive the development of AI-powered platforms for real-time monitoring of treatment efficacy. However, challenges persist, such as high R&D costs, stringent regulatory approvals, and data privacy concerns, which can hinder market expansion. Limitations in integrating these devices within existing infrastructure also pose significant barriers. Innovation should focus on wearable tech for continuous monitoring, improving interoperability of data systems, and refining precision medicine models through machine learning. Business growth could be fueled by prioritizing partnerships with biotech and pharma companies to foster integrated cancer care solutions. The market is inherently dynamic, influenced by rapid technological evolution and regulatory landscapes, necessitating adaptive strategies for sustained growth. Robust investments in R&D and strategic collaborations can bridge current technological gaps, while policy advocacy could ease regulatory constraints. Active engagement with patient communities to understand real-world needs will drive user-centric product development, enhancing adoption rates and market penetration.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Next-Generation Oncology Devices & Solutions Market

The Next-Generation Oncology Devices & Solutions Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing prevalence of cancer across the globe
  • Rising preference for minimally invasive techniques of diagnosis and treatment
  • Government Initiatives to improve healthcare infrastructure
• Market Restraints
  • High initial investments for manufacturing of next generation devices
• Market Opportunities
  • Ongoing technological advancements oncology testing and treatment
  • Proliferation of personalized and advanced genome medicine
• Market Challenges
  • Concern associated with the insufficient standardization of diagnostics

Porter's Five Forces: A Strategic Tool for Navigating the Next-Generation Oncology Devices & Solutions Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Next-Generation Oncology Devices & Solutions Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Next-Generation Oncology Devices & Solutions Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Next-Generation Oncology Devices & Solutions Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Next-Generation Oncology Devices & Solutions Market

A detailed market share analysis in the Next-Generation Oncology Devices & Solutions Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Next-Generation Oncology Devices & Solutions Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Next-Generation Oncology Devices & Solutions Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Next-Generation Oncology Devices & Solutions Market

A strategic analysis of the Next-Generation Oncology Devices & Solutions Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Next-Generation Oncology Devices & Solutions Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Brainlab, Danaher Corporation, Exact Sciences Corp., F. Hoffmann-La Roche Ltd., GE HealthCare Technologies, Inc., Guardant Health Inc., Hologic, Inc., Illumina, Inc., Johnson & Johnson Services Inc., Merck & Co., Inc., Myriad Genetics, Inc., NanoString Technologies, Inc., Natera, Inc., NeoGenomics, Inc., Novartis AG, Paige.AI, Inc., PerkinElmer, Inc., QIAGEN N.V., Quest Diagnostics Incorporated, Royal Philips, Siemens AG, Sysmex Corporation, Takara Bio USA, Inc., Thermo Fisher Scientific Inc., and Veracyte, Inc..

Market Segmentation & Coverage

This research report categorizes the Next-Generation Oncology Devices & Solutions Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Component, market is studied across Devices and Software. The Devices is further studied across Advanced Forms of Radiation Therapy and High-Intensity Focused Ultrasound.
• Based on Cancer Type, market is studied across Breast Cancer, Cervical Cancer, Colorectal Cancer, and Lung Cancer.
• Based on End User, market is studied across Diagnostic Imaging Centers and Hospitals.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing prevalence of cancer across the globe
    • 5.1.1.2. Rising preference for minimally invasive techniques of diagnosis and treatment
    • 5.1.1.3. Government Initiatives to improve healthcare infrastructure
  • 5.1.2. Restraints
    • 5.1.2.1. High initial investments for manufacturing of next generation devices
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing technological advancements oncology testing and treatment
    • 5.1.3.2. Proliferation of personalized and advanced genome medicine
  • 5.1.4. Challenges
    • 5.1.4.1. Concern associated with the insufficient standardization of diagnostics
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Next-Generation Oncology Devices & Solutions Market, by Component

• 6.1. Introduction
• 6.2. Devices
  • 6.2.1. Advanced Forms of Radiation Therapy
  • 6.2.2. High-Intensity Focused Ultrasound
• 6.3. Software

7. Next-Generation Oncology Devices & Solutions Market, by Cancer Type

• 7.1. Introduction
• 7.2. Breast Cancer
• 7.3. Cervical Cancer
• 7.4. Colorectal Cancer
• 7.5. Lung Cancer

8. Next-Generation Oncology Devices & Solutions Market, by End User

• 8.1. Introduction
• 8.2. Diagnostic Imaging Centers
• 8.3. Hospitals

9. Americas Next-Generation Oncology Devices & Solutions Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Next-Generation Oncology Devices & Solutions Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Next-Generation Oncology Devices & Solutions Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Agilent Technologies, Inc.
• 3. Bio-Rad Laboratories, Inc.
• 4. Brainlab
• 5. Danaher Corporation
• 6. Exact Sciences Corp.
• 7. F. Hoffmann-La Roche Ltd.
• 8. GE HealthCare Technologies, Inc.
• 9. Guardant Health Inc.
• 10. Hologic, Inc.
• 11. Illumina, Inc.
• 12. Johnson & Johnson Services Inc.
• 13. Merck & Co., Inc.
• 14. Myriad Genetics, Inc.
• 15. NanoString Technologies, Inc.
• 16. Natera, Inc.
• 17. NeoGenomics, Inc.
• 18. Novartis AG
• 19. Paige.AI, Inc.
• 20. PerkinElmer, Inc.
• 21. QIAGEN N.V.
• 22. Quest Diagnostics Incorporated
• 23. Royal Philips
• 24. Siemens AG
• 25. Sysmex Corporation
• 26. Takara Bio USA, Inc.
• 27. Thermo Fisher Scientific Inc.
• 28. Veracyte, Inc.